The Sencell sensor will invisible once it is injected under a person’s skin and is expected to last for a minimum of six months without calibration. The technology will have a range of use cases and can be applied by medical professionals, people with diabetes and high-performance professionals such as professional athletes, firefighters, and soldiers.

The prototypes of Sencell were evaluated in-vitro to achieve performance data and to demonstrate the working principle. Proof of concept of the proprietary osmotic pressure sensing technology has been successfully performed in two preclinical trials in pigs in 2016 and 2017.

The results proved that the Lifecare osmotic pressure technology is able to track interstitial glucose and provide stable references.

In 2023 Lifecare’s first-in-human study confirm clinical accuracy in line with gold standard. Data from study LFC-SEN-001 show that the Sencell-sensor has a solid clinical accuracy with a mean average of relative difference (MARD) of 9,6%.

In 2023 a longevity experiment of Sencell Continuous Glucose Monitoring (CGM) sensor reached an operational lifetime of more than 24 weeks (172 days). This was carried out with a sensor chemistry shelf life of almost 27 weeks (187 days).

We have achieved regulatory approval from The Norwegian Food Safety Authority (NFSA) to start LFC-SEN-002 in 2024.

Study LFC-SEN-002 will be carried out in collaboration with The Norwegian University of Life Sciences (NMBU) located at Ås, Norway. Lifecare has received approval from the authority to complete the study on dogs.

Lifecare expects substantial development progress for the Sencell Osmotic Sensor technology. The company reached the target for pilot production in Q1 2024 and launch of an automated production line by end of Q2 2024 is set as a major milestone. Lifecare will later on prepare to initiate the CE mark approval process for the Sencell osmotic pressure sensor technology.